Mifepristone-Misoprostol

• Medication Abortion
• Early Pregnancy Termination

The combination of mifepristone followed by misoprostol is the FDA-approved regimen for medical termination of intrauterine pregnancy through 70 days (10 weeks) of gestation. Mifepristone (Mifeprex) is a progesterone-receptor antagonist that destabilizes the early pregnancy, and misoprostol is a prostaglandin E1 analog that produces the cervical softening and uterine contractions needed to complete the process. When taken in sequence, the regimen achieves complete termination in roughly 95-98% of eligible pregnancies. The medication is dispensed under the FDA's Risk Evaluation and Mitigation Strategy (REMS) program by certified prescribers and pharmacies, and Florida law restricts dispensing — patients should confirm current state-level requirements before starting. Beyond elective termination, the regimen is widely used for management of early pregnancy loss (missed or incomplete miscarriage), where it provides a non-surgical alternative to expectant management or uterine aspiration with comparable safety and high patient satisfaction.

Mechanism of Action

Mifepristone is a synthetic 19-norsteroid that binds the progesterone receptor with greater affinity than progesterone itself but produces no agonist activity. By displacing progesterone — the hormone that maintains decidual integrity, suppresses uterine contractility, and keeps the cervix closed during pregnancy — mifepristone causes decidual breakdown, detachment of the gestational sac, cervical softening, and upregulation of myometrial prostaglandin receptors. It also has weak glucocorticoid-receptor antagonism, which is the basis for one of its main contraindications (chronic adrenal failure) and is exploited in higher doses for the treatment of Cushing syndrome. Misoprostol, given 24-48 hours later, then exploits the prostaglandin sensitization that mifepristone has produced: it binds prostaglandin E receptors on uterine smooth muscle, triggering coordinated contractions that expel the gestational tissue and completing what mifepristone began. Used alone, either drug is far less effective; the sequential combination is what produces the high success rate. Misoprostol also acts on the cervix to soften and dilate it, reducing trauma during expulsion. The pharmacokinetics are well characterized: mifepristone has a long half-life of about 18 hours, and misoprostol's active metabolite peaks within 30 minutes of administration and is cleared rapidly.

Clinical Use

The regimen is used for medical management of early pregnancy loss as well as for elective pregnancy termination through 70 days from the first day of the last menstrual period. Eligibility requires an intrauterine pregnancy (ectopic pregnancy must be excluded), gestational age within the approved window confirmed by last menstrual period, examination, or ultrasound, and absence of contraindications. Patients should have access to emergency care, transportation, a support person if desired, and a comfortable place to stay during the heaviest bleeding. Suction aspiration is the alternative for those outside the gestational window, those who prefer a single in-clinic procedure, or those for whom medical management fails. Counseling per ACOG Practice Bulletin 225 covers efficacy, expected bleeding, pain control, follow-up requirements, and contraception planning before discharge. The regimen is also an option for patients with a desired pregnancy in whom fetal demise has occurred, where it shortens time to complete passage compared with expectant management. Telehealth provision and mail-order pharmacy dispensing have expanded under updated REMS rules, though state laws vary considerably and Florida has restrictions that should be reviewed before initiating treatment.

How to Take It

Mifepristone 200 mg is swallowed in the office or as directed by the prescriber. Twenty-four to 48 hours later, four 200 mcg misoprostol tablets (800 mcg total) are placed buccally — two tablets between the cheek and gum on each side — held for 30 minutes, then any remaining fragments swallowed with water. Vaginal or sublingual administration is an evidence-based alternative for patients who cannot tolerate buccal use. Take ibuprofen 600-800 mg about 30 minutes before the misoprostol to reduce cramping; combining with acetaminophen is reasonable, and many patients also use a heating pad on the lower abdomen. Heavy bleeding and strong cramping typically begin 1-4 hours after misoprostol and peak over the next several hours; passage of clots and tissue (sometimes including the gestational sac) is expected. Lighter bleeding and spotting can continue for 1-2 weeks, with most patients returning to baseline by 3-4 weeks. Avoid tampons, intercourse, and submersion in water (baths, pools, hot tubs) during heavy bleeding to reduce infection risk; pads are recommended. Plan to be at home with no major obligations during the 24 hours after misoprostol. If bleeding does not start within 24 hours of misoprostol, a second dose may be considered or alternative management pursued — contact the prescribing clinician.

Monitoring and Follow-Up

A follow-up assessment within 7-14 days confirms complete termination — this can be done with serial quantitative hCG levels (an 80% drop from pre-treatment is reassuring), a high-sensitivity urine pregnancy test combined with symptom review, or transvaginal ultrasound. Persistent pregnancy or significant retained tissue requires either repeat misoprostol or aspiration. Rh-negative patients may receive Rh immunoglobulin, although recent Society of Family Planning guidance suggests Rh testing and prophylaxis can often be deferred before 12 weeks gestation given the negligible risk of alloimmunization. Hemoglobin can be checked if bleeding seems excessive — review of your CBC helps identify anemia and informs whether iron supplementation is needed. Contraception planning starts at the follow-up visit; ovulation can resume within 8 days, so a chosen method should be in place quickly. Options include a same-visit IUD insertion (levonorgestrel or copper), etonogestrel implant, norethindrone or combined oral contraceptives, depot medroxyprogesterone, or barrier methods. Emotional support, including referral for counseling if needed, is part of comprehensive aftercare.

Special Populations

Contraindications include confirmed or suspected ectopic pregnancy, IUD in place (must be removed first), chronic adrenal failure, concurrent long-term systemic corticosteroids, inherited porphyrias, hemorrhagic disorders or anticoagulation with agents like warfarin or apixaban, and known hypersensitivity to either drug. The regimen has not been studied beyond 70 days gestation in the FDA approval. Adolescents under 18 may use the regimen with the same medical considerations; counseling about confidentiality, support, and Florida parental notification or consent requirements is important. Patients with severe asthma should use misoprostol with caution because of potential bronchospasm. Lactation is not a contraindication; both drugs have minimal milk transfer and breastfeeding can continue. Patients with hereditary or acquired bleeding disorders, severe anemia, or significant cardiovascular disease may require closer monitoring or in-clinic management.

When to Contact Your Doctor

Seek emergency care for soaking through more than two thick maxi-pads per hour for two consecutive hours, fever above 100.4 F lasting more than 24 hours after misoprostol, severe abdominal pain not relieved by ibuprofen and rest, foul-smelling vaginal discharge, dizziness or fainting suggesting significant blood loss, persistent vomiting or diarrhea more than 24 hours after misoprostol, or no bleeding at all within 24 hours of the misoprostol dose. These can signal hemorrhage, infection (rare but potentially serious), or treatment failure including ongoing pregnancy. Worsening pain that begins more than 3-5 days after the regimen warrants prompt evaluation for endometritis or retained products.

Practical counseling points reduce anxiety and improve outcomes. Patients should plan for the misoprostol step at a time when they can remain home for at least 12-24 hours with rest, hydration, and accessible bathroom facilities. Comfort measures include a heating pad, ibuprofen at a regular schedule for the first 24 hours, soft foods, and supportive companions. The experience is often described as similar to a heavy menstrual period with strong cramping, although individual variation is considerable; some patients report mild bleeding while others have a more intense experience. Resumption of normal activities, work, and exercise typically occurs within a few days as bleeding tapers. Future fertility is not impaired by appropriate medical management; patients can conceive in subsequent cycles if desired and should ensure reliable contraception is in place if pregnancy is to be avoided. Emotional reactions vary widely and may evolve over weeks to months — relief, sadness, ambivalence, and a complex mixture are all normal, and access to confidential, non-judgmental counseling is part of comprehensive aftercare.

For confidential counseling about pregnancy options, contraception planning, miscarriage management, and follow-up care, contact us or schedule a visit at Zimmer Medical Group.